Brimonidine Tartrate Patent Expiration
Brimonidine Tartrate was first introduced by Allergan Inc
Brimonidine Tartrate Patents
Given below is the list of patents protecting Brimonidine Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Alphagan P | US10307368 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P |
US5424078 (Pediatric) | Aqueous ophthalmic formulations and methods for preserving same |
Dec 13, 2012
(Expired) | Abbvie |
| Alphagan P | US6562873 | Compositions containing therapeutically active components having enhanced solubility |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P |
US6562873 (Pediatric) | Compositions containing therapeutically active components having enhanced solubility |
Jan 10, 2022
(Expired) | Abbvie |
| Alphagan P | US6627210 | Compositions containing α-2-adrenergic agonist components |
Jul 18, 2021
(Expired) | Abbvie |
| Alphagan P |
US6627210 (Pediatric) | Compositions containing α-2-adrenergic agonist components |
Jan 18, 2022
(Expired) | Abbvie |
| Alphagan P | US6641834 | Compositions containing alpha-2-adrenergic agonist components |
Jul 28, 2021
(Expired) | Abbvie |
| Alphagan P |
US6641834 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 28, 2022
(Expired) | Abbvie |
| Alphagan P | US6673337 | Compositions containing alpha-2-adrenergic agonist components |
Jul 26, 2021
(Expired) | Abbvie |
| Alphagan P |
US6673337 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 26, 2022
(Expired) | Abbvie |
| Alphagan P | US8858961 | Compositions containing alpha-2-adrenergic agonist components |
Sep 02, 2023
(Expired) | Abbvie |
| Alphagan P |
US8858961 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Mar 02, 2024
(Expired) | Abbvie |
| Alphagan P | US9295641 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P |
US9295641 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 10, 2022
(Expired) | Abbvie |
| Alphagan P | US9687443 | Compositions containing alpha-2-adrenergic agonist components |
Jul 10, 2021
(Expired) | Abbvie |
| Alphagan P |
US9687443 (Pediatric) | Compositions containing alpha-2-adrenergic agonist components |
Jan 10, 2022
(Expired) | Abbvie |
| Lumify | US11596600 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Lumify | US11833245 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Lumify | US8293742 | Preferential vasoconstriction compositions and methods of use | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify | US9259425 | Compositions and methods for eye whitening | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify Preservative Free | US11596600 | Vasoconstriction compositions and methods of use | Jul 27, 2029 | Bausch And Lomb Inc |
| Lumify Preservative Free | US8293742 | Preferential vasoconstriction compositions and methods of use | Jul 14, 2030 | Bausch And Lomb Inc |
| Lumify Preservative Free | US9259425 | Compositions and methods for eye whitening | Jul 14, 2030 | Bausch And Lomb Inc |
| Mirvaso | US10201517 | Brimonidine gel compositions and methods of use | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US7439241 | Compounds, formulations, and methods for treating or preventing rosacea | Aug 25, 2025 | Galderma Labs Lp |
| Mirvaso | US8053427 | Brimonidine gel composition | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US8163725 | Gel compositions and methods of use | Jun 13, 2031 | Galderma Labs Lp |
| Mirvaso | US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8410102 | Methods and compositions for treating or preventing erythema | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | May 24, 2025 | Galderma Labs Lp |
| Mirvaso | US8513247 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US8513249 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May 25, 2024
(Expired) | Galderma Labs Lp |
| Mirvaso | US9861631 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Mirvaso | US9861632 | Methods and compositions for safe and effective treatment of erythema | Mar 25, 2031 | Galderma Labs Lp |
| Qoliana | US7265117 | Topical brimonidine tartrate formulations that lack chlorine dioxide | Aug 19, 2025 | Sandoz |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brimonidine Tartrate's patents.
Latest Legal Activities on Brimonidine Tartrate's Patents
Given below is the list recent legal activities going on the following patents of Brimonidine Tartrate.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Feb, 2019 | US7265117 |
| Patent Issue Date Used in PTA Calculation | 04 Sep, 2007 | US7265117 |
| Recordation of Patent Grant Mailed | 04 Sep, 2007 | US7265117 |
| Issue Notification Mailed | 15 Aug, 2007 | US7265117 |
| Dispatch to FDC | 31 Jul, 2007 | US7265117 |
| Application Is Considered Ready for Issue | 13 Jul, 2007 | US7265117 |
| Issue Fee Payment Received | 09 Jul, 2007 | US7265117 |
| Issue Fee Payment Verified | 09 Jul, 2007 | US7265117 |
| Mail Notice of Allowance | 27 Jun, 2007 | US7265117 |
| Notice of Allowance Data Verification Completed | 23 Jun, 2007 | US7265117 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Brimonidine Tartrate Generics
Several generic applications have been filed for Brimonidine Tartrate. The first generic version for Brimonidine Tartrate was by Bausch And Lomb Pharmaceuticals Inc and was approved on May 28, 2003. And the latest generic version is by Upsher Smith Laboratories Llc and was approved on Jun 12, 2024.
Given below is the list of companies who have filed for Brimonidine Tartrate generic.
1. RISING
Rising Pharma Holdings Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 14, 2006 |
2. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Nov 22, 2023 |
3. UPSHER SMITH LABS
Upsher Smith Laboratories Llc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Upsher Smith Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Jun 12, 2024 |
4. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Jan 30, 2008 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Mar 4, 2024 |
5. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 11, 2019 |
6. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 29, 2023 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Aug 1, 2023 |
7. INDOCO
Indoco Remedies Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Indoco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Prescription | OPHTHALMIC | AT | Nov 18, 2014 |
8. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15% | solution/drops | Prescription | OPHTHALMIC | AT | Jan 31, 2022 |
| 0.1% | solution/drops | Prescription | OPHTHALMIC | AB | Dec 21, 2022 |
9. BAUSCH AND LOMB
Bausch And Lomb Pharmaceuticals Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Bausch And Lomb.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2%
(reference standard) | solution/drops | Prescription | OPHTHALMIC | AT | May 28, 2003 |
10. TEVA PARENTERAL
Teva Parenteral Medicines Inc has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Teva Parenteral.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | solution/drops | Discontinued | OPHTHALMIC | N/A | Sep 10, 2004 |
11. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.025% | solution/drops | Over the counter | OPHTHALMIC | N/A | Feb 16, 2024 |
12. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Brimonidine Tartrate. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.33% BASE | gel | Prescription | TOPICAL | AB | Sep 23, 2021 |